La vendita allo scoperto per Nu Skin Enterprises dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Nu Skin Enterprises. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Nu Skin Enterprises (NYSE:NUS) Azioni, Report sulle vendite allo scoperto

Nu Skin Enterprises

Nu Skin Enterprises Inc is a health and beauty direct-selling company. It has two primary product categories: beauty products and wellness products. The company develops and distributes nutritional, weight-management products, and food supplements under the Nu Skin and Pharmanex brands, respectively. The company has operations internationally, in more than 50 countries across the Americas, Europe, and the Asia-Pacific.

Nu Skin Enterprises Inc

Nuveen ESG 1-5 Year U.S. Aggregate Bond ETF

Nuveen Ultra Short Income ETF

Nuveen ESG Small-Cap ETF

NEOS ETF Trust NEOS Nasdaq-100 Hedged Equity Income ETF

NAUTILUS MINERALS INC ORD by Nautilus Minerals Inc.

NEW SOURCE ENGY PFD UTS by New Source Energy Partners LP

News

Guidance

Nu Skin Sees Q4 Adj. EPS $0.19-$0.29 vs $0.28 Est., Revenue $410M-$445M vs $455.83M Est.; Sees 2024 Adj. EPS $0.65-$0.75 vs $0.77 Est., Revenue $1.7B-$1.73B vs $1.75B Est.

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.14 by 21.43 percent. The company reported quarterly sales of $430.100 million which missed the analyst consensus estimate of $440.954 million by 2.46 percent. This is a 13.77 percent decrease over sales of $498.772 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Nu Skin Enterprises Q3 2024 GAAP EPS $0.17 Beats $0.14 Estimate, Sales $430.100M Miss $440.954M Estimate

Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>) is driving its growth strategy through key initiatives that aim to revitalize its market presence and tap into high-growth areas. The company continues to prioritize thoughtful product introductions that align with shifting consumer preferences. A recent example is the launch of MYND360, a new line of clinically validated nutritional formulas tailored to support cognitive well-being.
Featuring six products, MYND360 is designed to enable users to manage stress, remain focused, enhance memory and sleep better. This innovation reflects Nu Skin&#39;s focus on the fast-growing brain health market. While these upsides, along with strength in the Rhyz business, have been working well. Nu Skin remains troubled by persistent macroeconomic obstacles.
<h2>Product Launches a Key Driver for Nu Skin</h2>
With the help of advanced technology and well-strategized product programs, Nu Skin tries to capture greater market share and maintain growth momentum. The company&#39;s long-term strategies stand on three key pillars &mdash; Products, Programs and Platforms. NUS has been successfully launching innovative beauty devices, which have become an important part of its growth.
Nu Skin&#39;s second-quarter 2024 results included positive contributions from new products such as Ageloc, Wellspa IO and RenewspA IO, along with the company&#39;s TRME weight management system. The ageLOC WellSpa iO has been a solid addition to the company&#39;s beauty device system brands, generating impressive response.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/78/81418.jpg?v=533402966" />
Image Source: Zacks Investment Research
<h2>Nu Skin Gains From Rhyz Business</h2>
Nu Skin&#39;s Rhyz business emerges as a cornerstone of its strategic vision, highlighted by its remarkable growth trajectory and significant contribution to the company&#39;s revenue stream. Rhyz represents a cohesive ecosystem comprising consumer, technology, and manufacturing entities, all dedicated to pioneering innovation within the realms of beauty, wellness, and lifestyle. Experiencing 32.3% revenue growth in the second quarter of 2024, Rhyz accounted for 15% of total enterprise revenues and is anticipated to reach 20% to 25% by 2025.
The success of this business reflects Nu Skin&#39;s commitment to capitalizing on evolving consumer trends, particularly in influencer and affiliate marketing, which are projected to surge in the coming years. By investing in Rhyz&#39;s manufacturing capabilities, technology advancements, and creator-led indie beauty brands, Nu Skin is strategically positioning itself to drive sustained growth and value creation within the beauty, wellness, and lifestyle market.
<h2>Challenges Faced by NUS</h2>
Nu Skin&#39;s second-quarter 2024 performance was hurt by continuous macroeconomic headwinds across most regions, which weighed on consumer spending and customer acquisition, especially for premium products. The company also grappled with pressures in the direct selling industry. These headwinds, along with foreign adverse currency fluctuations, hurt Nu Skin&#39;s quarterly revenues, which tumbled 12.2% year over year to $439.1 million in the second quarter.
The operating environment for Nu Skin&#39;s core business remains challenging, primarily due to macroeconomic factors and pressures within the direct selling industry. Taking into account the company&#39;s first-half 2024 performance and rising foreign exchange headwinds, management tightened the annual guidance range for 2024 in its second-quarter earnings release.
Nu Skin now anticipates revenues in the band of $1.73-$1.81 billion for 2024, which suggests a 12-8% decline from the year-ago period&#39;s reported figure. Earlier, the metric was expected to be in the range of $1.73-$1.87 billion. Management envisions adjusted earnings per share of 75-95 cents. The projection suggests a decline from adjusted earnings of $1.85 recorded in 2023. Management had earlier envisioned an adjusted EPS of 95 cents to $1.35 for 2024.
For the third quarter of 2024, the company expects revenues between $430 million and $465 million, which suggests a decline of 14% to 7% from the year-ago quarter&#39;s reported level. The company expects adjusted EPS of 15-25 cents in the third quarter of 2024 compared with 56 cents recorded in the same period last year. Shares of NUS have plunged 42.6% in the past three months compared with the industry&#39;s decline of 10%.
<h2>Final Words on NUS</h2>
Nu Skin continues to drive growth through strategic initiatives, innovative product launches, and the expanding Rhyz business. While the company has made significant strides in capturing market opportunities, especially in the beauty and brain health sectors, it faces ongoing challenges from macroeconomic pressures and headwinds in the direct selling industry. Moving forward, the Zacks Rank #3 (Hold) company&#39;s ability to balance innovation with market realities will be key to sustaining its growth trajectory.
<h2>Top 3 Staple Bets</h2>
Inter Parfums (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ipar#NASDAQ">IPAR</a>) is engaged in the manufacturing, distribution and marketing of a wide range of fragrances and related products. It currently carries a Zacks Rank of 2 (Buy).
The Zacks Consensus Estimate for IPAR&#39;s current financial-year sales and earnings indicates advancements of 10.2% and 8.4%, respectively, from the prior-year figures. It has a trailing four-quarter earnings surprise of 2.5%, on average.
Flowers Foods (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/flo#NYSE">FLO</a>), one of the largest producers of packaged bakery foods in the United States, currently carries a Zacks Rank #2. FLO has a trailing four-quarter earnings surprise of 1.9%, on average.
The Zacks Consensus Estimate for Flowers Foods&#39; current financial-year sales and earnings implies growth of around 1% and 5%, respectively, from the year-ago reported numbers.
McCormick &amp; Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mkc#NYSE">MKC</a>) is a leading manufacturer, marketer and distributor of spices, seasonings, specialty foods and flavors. It currently carries a Zacks Rank #2.
The Zacks Consensus Estimate for McCormick &amp; Company&#39;s current fiscal-year sales and earnings indicates advancements of 0.6% and 8.2%, respectively, from the year-ago reported figures. MKC has a trailing four-quarter earnings surprise of 13.8%, on average.
<a href="https://www.zacks.com/stock/news/2351561/nu-skin-navigates-growth-with-innovation-amid-industry-challenges?cid=CS-BENZ-FT-analyst_blog|rank_focused-2351561">To read this article on Zacks.com click here.</a>

Large Cap

Macro Economic Events

Mid Cap

Small Cap

Management

Economics

Markets

Analyst Ratings

Trading Ideas

IPAR

Nu Skin Navigates Growth With Innovation Amid Industry Challenges

MYND360 provides holistic, cognitive support for core areas of mental well-being, including sleep, calm, focus and memory
Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>), a global beauty and wellness leader, today introduced MYND360, a new line of clinically proven nutritional formulas to support core needs for cognitive well-being. MYND360 is the culmination of five years of research and clinical studies, and features six products designed to help users sleep better, manage stress, stay focused and even support a strong memory.

Biotech

General

Nu Skin Introduces MYND360, A New Line Of Clinically Proven Supplements And Topicals For Mental Well-Being

Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>) has not been in its best shape lately, with its shares down 27.7% in the past three months compared with the industry&#39;s 21.3% decline. Additionally, this beauty and wellness product company has trailed the broader Zacks Consumer Staples sector and the S&amp;P 500&#39;s respective growth of 1.2% and 4.2%.
Despite being a prominent player in the beauty and wellness industry, Nu Skin has struggled to navigate a series of macroeconomic headwinds that have dampened consumer spending, particularly on premium products. Additionally, the company has been severely impacted by stronger-than-expected foreign currency fluctuations and ongoing pressures within the direct selling industry, contributing to a disappointing second-quarter 2024 performance.
Considering the company&#39;s first-half 2024 performance and rising foreign exchange headwinds, management tightened the annual guidance range for 2024 in its second-quarter earnings release.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/a3/74745.jpg?v=1909197970" />
Image Source: Zacks Investment Research
<h3>Macroeconomic Hurdles Persist</h3>
Nu Skin has been encountering persistent macroeconomic obstacles, which continued in the second quarter of 2024. The company&#39;s performance was hurt by continuous macroeconomic headwinds across most regions, which weighed on consumer spending and customer acquisition, especially for premium products. Additionally, NUS grappled with pressures in the direct selling industry.
These headwinds, along with foreign adverse currency fluctuations, hurt Nu Skin&#39;s quarterly revenues, which tumbled 12.2% year over year to $439.1 million in the second quarter. On a constant-currency basis, revenues fell 8%.&nbsp; Sales leaders were down 16% year over year to 38,592. Nu Skin&#39;s customer base dropped 14% to 893,514. The company&#39;s paid affiliates were down 17% to 155,486. On an adjusted basis, paid affiliates tumbled 9%.
<h3>Volatile Currency Movements</h3>
Nu Skin&#39;s strong international presence exposes it to the risk of volatile currency movements. Any adverse currency fluctuation is likely to weigh on the company&#39;s operating performance. Nu Skin&#39;s second-quarter 2024 revenues witnessed strong currency headwinds. Revenues included a negative impact of 4.2% from foreign currency fluctuations. The company envisions unfavorable foreign currency impacts of around 4-3% on third-quarter and 2024 revenues.
<h3>Bumpy Road Ahead</h3>
The operating environment for Nu Skin&#39;s core business remains challenging, primarily due to macroeconomic factors and pressures within the direct selling industry. Nu Skin now anticipates revenues in the band of $1.73-$1.81 billion for 2024, which suggests a 12-8% decline from the year-ago period&#39;s reported figure. Earlier, the metric was expected in the range of $1.73-$1.87 billion. Management envisions an adjusted earnings per share of 75-95 cents. The projection suggests a decline from adjusted earnings of $1.85 recorded in 2023. Management had earlier envisioned an adjusted EPS of 95 cents to $1.35 for 2024.
For the third quarter of 2024, the company expects revenues between $430 million and $465 million, which suggests a decline of 14% to 7% from the year-ago quarter&#39;s reported level. NUS expects adjusted earnings in the band of 15-25 cents a share in the third quarter compared with 56 cents recorded in the same period last year.
<h3>Estimates Lose Sheen</h3>
The Zacks Consensus Estimate for 2024 earnings per share has declined from $1.10 to 78 cents over the past 30 days. The consensus estimate for the third-quarter EPS has tumbled from 48 to 20 cents in the same time frame. This downward adjustment reflects a negative sentiment among analysts and suggests potential challenges in achieving projected profitability.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/37/74746.jpg?v=388068093" />
Image Source: Zacks Investment Research
<h3>Wrapping Up</h3>
Nu Skin is navigating through a turbulent period, with its stock performance reflecting the ongoing macroeconomic and industry-specific challenges. While the company is actively pursuing strategic initiatives to reinvigorate its market presence and drive growth through new product launches and the strength of its Rhyz business, these efforts may take time to bear fruit. In the near term, the combination of persistent headwinds and tighter guidance suggests that Nu Skin faces a difficult road ahead.
Investors should remain cautious, keeping a close eye on how the company manages these challenges and whether its strategic initiatives can offset the current pressures. Nu Skin presently carries a Zacks Rank #5 (Strong Sell).
<h3>Better-Ranked Staple Bets</h3>
The Chef&#39;s Warehouse (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chef#NASDAQ">CHEF</a>), which distributes specialty food and center-of-the-plate products, has a trailing four-quarter earnings surprise of 33.7%, on average. CHEF currently sports a Zacks Rank #1 (Strong Buy).
The Zacks Consensus Estimate for The Chef&#39;s Warehouse&#39;s current financial-year sales and earnings calls for growth of 9.7% and 12.6%, respectively, from the prior-year reported level.
Vital Farms (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vitl#NASDAQ">VITL</a>) offers a range of produced pasture-raised foods. It currently carries a Zacks Rank #2 (Buy). VITL has a trailing four-quarter earnings surprise of 82.5%, on average.
The Zacks Consensus Estimate for Vital Farms&#39; current financial-year earnings indicates growth of 72.9% from the year-ago reported numbers.
Nomad Foods (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nomd#NYSE">NOMD</a>), carrying a Zacks Rank #2, manufactures and distributes frozen foods. NOMD has a trailing four-quarter earnings surprise of 3.1%, on average.
The Zacks Consensus Estimate for Nomad Foods&#39; current financial-year sales and earnings implies growth of 4.3% and 11.5%, respectively, from the prior-year reported level.
<a href="https://www.zacks.com/stock/news/2324418/nu-skin-nus-down-28-in-3-months-what-s-the-next-best-move?cid=CS-BENZ-FT-analyst_blog|rank_focused-2324418">To read this article on Zacks.com click here.</a>

CHEF

NOMD

VITL

Nu Skin Down 28% in 3 Months: What's the Next Best Move?

DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) with a Neutral and lowers the price target from $12.5 to $11.

Price Target

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $11

WIIM

Nu Skin Enterprises shares are trading lower. Citigroup maintained a Neutral rating on the stock and lowered its price target from $14 to $11.5.

Citigroup analyst Chasen Bender maintains Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) with a Neutral and lowers the price target from $14 to $11.5.

Citigroup Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $11.5

Nu Skin Enterprises Revises FY24 Revenue Forecast From $1.73B - $1.87B To $1.73B - $1.81B (Est $1.77B), Cuts Adj EPS Outlook From $0.95 - $1.35 To $0.75 - $0.95 (Est $1.10)

Nu Skin Enterprises Expects Q3 Revenue Of $430M - $465M, Est $459.86M; Adj EPS Of $0.15 - $0.25, Est $0.42

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.17 by 23.53 percent. This is a 61.11 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $439.081 million which beat the analyst consensus estimate of $431.871 million by 1.67 percent. This is a 12.23 percent decrease over sales of $500.257 million the same period last year.

Nu Skin Enterprises Q2 2024 Adj. EPS $0.21 Beats $0.17 Estimate, Sales $439.081M Beat $431.871M Estimate

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said he likes Pure Storage, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>), adding that it is a &#8220;<a href="https://www.benzinga.com/quote/PSTG/earnings">fabulous&#8221; company</a>.
Pure Storage is expected to host a conference call on Wednesday, May 29 to discuss its financial results for the first quarter fiscal year 2025.
&#8220;Anything connected with EVs right now is a no go,&#8221; Cramer said when asked about Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).
On May 1, Albemarle reported mixed results for the first quarter.
When asked about AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>), he said, &#8220;We've been behind AeroVironment forever, and the reason is that they make drones that are much less expensive than the other stuff the military buys.&#8221;
On March 4, AeroVironment said third-quarter revenue increased 39% year-over-year to $186.6 million, which beat the consensus estimate of $170.625 million.
The &#8220;Mad Money&#8221; host said Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) is an &#8220;overvalued&#8221; stock even at these prices.
On May 8, Nu Skin Enterprises posted weaker-than-expected quarterly results.
AllianceBernstein Holding L.P. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) is a &#8220;very well-run&#8221; company, Cramer said. &#8220;Always surprised that it is as inexpensive as it is.&#8221;
On April 25, AllianceBernstein posted better-than-expected first-quarter earnings results.
When asked about MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), Jim Cramer said, &#8220;If you want Bitcoin, don't buy MicroStrategy.&#8221;
On April 29, MicroStrategy reported worse-than-expected first-quarter financial results.
&#8220;These are infrastructure plays that are working because that money is starting to pour in from the federal government. That's why that's a winner,&#8221; Cramer said when asked about Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>).
On May 6, Sterling Infrastructure reported better-than-expected first-quarter financial results.
Price Action:
<ul>
<li>AllianceBernstein shares rose 0.2% to settle at $32.65 on Monday.</li>
<li>Pure Storage shares fell 0.2% to close at $54.33.</li>
<li>Albemarle shares rose 1.5% to settle at $131.51 on Monday.</li>
<li>MicroStrategy shares gained 5.6% to settle at $1,245.96.</li>
<li>AeroVironment shares rose 0.4% to close at $187.28 on Monday.</li>
<li>Sterling Infrastructure shares fell 0.6% to settle at $128.08 on Monday.</li>
<li>Nu Skin shares gained 2.2% to close at $13.51.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/news/24/05/38788200/top-5-tech-stocks-that-may-plunge-in-q2">Top 5 Tech Stocks That May Plunge In Q2</a>

Media

AVAV

MSTR

PSTG

STRL

Jim Cramer Says Nu Skin Is 'Overvalued,' Praises 'Fabulous' Pure Storage

DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) with a Neutral and lowers the price target from $15.5 to $12.5.

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $12.5

Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.05 by 120 percent. The company reported quarterly sales of $417.300 million which missed the analyst consensus estimate of $426.561 million by 2.17 percent. This is a 13.33 percent decrease over sales of $481.462 million the same period last year.

Nu Skin Enterprises Q1 2024 Adj EPS $(0.01) Misses $0.05 Estimate, Sales $417.300M Miss $426.561M Estimate

On March 06, 2024, Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>) will distribute a dividend payout of $0.06 per share, equating to an annualized dividend yield of 1.38%. Shareholders who owned the stock before the ex-dividend date on February 23, 2024 will receive this payout.
<h3>Nu Skin Enterprises Recent Dividend Payouts</h3>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style><table>
<thead>
<tr>
<th>Ex-Date</th>
<th style="text-align: right;">Payments per year</th>
<th>Dividend</th>
<th>Yield</th>
<th>Announced</th>
<th>Record</th>
<th>Payable</th>
</tr>
</thead>
<tbody>
<tr>
<td>2024-02-23</td>
<td style="text-align: right;">4</td>
<td>$0.06</td>
<td>1.38%</td>
<td>2024-02-14</td>
<td>2024-02-26</td>
<td>2024-03-06</td>
</tr>
<tr>
<td>2023-11-22</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>8.21%</td>
<td>2023-11-01</td>
<td>2023-11-24</td>
<td>2023-12-06</td>
</tr>
<tr>
<td>2023-08-24</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>5.31%</td>
<td>2023-08-01</td>
<td>2023-08-25</td>
<td>2023-09-06</td>
</tr>
<tr>
<td>2023-05-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.91%</td>
<td>2023-05-03</td>
<td>2023-05-26</td>
<td>2023-06-07</td>
</tr>
<tr>
<td>2023-02-24</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.6%</td>
<td>2023-02-15</td>
<td>2023-02-27</td>
<td>2023-03-08</td>
</tr>
<tr>
<td>2022-11-23</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.93%</td>
<td>2022-11-02</td>
<td>2022-11-25</td>
<td>2022-12-07</td>
</tr>
<tr>
<td>2022-08-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.43%</td>
<td>2022-08-04</td>
<td>2022-08-26</td>
<td>2022-09-07</td>
</tr>
<tr>
<td>2022-05-26</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.45%</td>
<td>2022-05-04</td>
<td>2022-05-27</td>
<td>2022-06-08</td>
</tr>
<tr>
<td>2022-02-25</td>
<td style="text-align: right;">4</td>
<td>$0.39</td>
<td>3.1%</td>
<td>2022-02-16</td>
<td>2022-02-28</td>
<td>2022-03-09</td>
</tr>
<tr>
<td>2021-11-24</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>3.78%</td>
<td>2021-11-03</td>
<td>2021-11-26</td>
<td>2021-12-08</td>
</tr>
<tr>
<td>2021-08-26</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>2.8%</td>
<td>2021-08-04</td>
<td>2021-08-27</td>
<td>2021-09-08</td>
</tr>
<tr>
<td>2021-05-27</td>
<td style="text-align: right;">4</td>
<td>$0.38</td>
<td>2.92%</td>
<td>2021-05-05</td>
<td>2021-05-28</td>
<td>2021-06-09</td>
</tr>
</tbody>
</table>
Nu Skin Enterprises lags behind its industry peers in terms of dividend yield, with Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>) surpassing it with a higher annualized dividend yield of 17.00%.
<h3>Analyzing Nu Skin Enterprises Financial Health</h3>
Companies that pay out steady cash dividends are attractive to income-seeking investors, and companies that are financially healthy tend to maintain their dividend payout schedule. For this reason, investors can find it insightful to see if a company has been increasing or decreasing their dividend payout schedule and if their earnings are growing. 
<h3>YoY Growth in Dividend Per Share</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709737512_0.png" alt="dividend chart graph" />
Investors witnessed an upward trajectory in the company's dividend per share between 2020 and 2023. The dividend per share rose from $1.50 to $1.56, indicating the company's dedication to enhancing shareholder value through increased dividends.
<h3>YoY Earnings Growth For Nu Skin Enterprises</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1709737512_1.png" alt="earning chart graph" />
From 2020 to 2023, Nu Skin Enterprises experienced a decrease in earnings per share, dropping from $2.97 to $2.36. This declining earnings trend may be worrisome for income-seeking investors, as it indicates a potential impact on the company's ability to sustain or increase its cash dividend payouts. Further analysis is necessary to understand the underlying reasons for this decrease.
<h3>Recap</h3>
In this article, we explore the recent dividend payout of Nu Skin Enterprises and its significance for shareholders. The company has decided to distribute a dividend of $0.06 per share today, which equates to an annualized dividend yield of 1.38%.
Nu Skin Enterprises lags behind its industry peers in terms of dividend yield, with Medifast surpassing it with a higher annualized dividend yield of 17.00%.
With dividend per share increasing and earnings per share decreasing from 2020 to 2023, Nu Skin Enterprises seems to be emphasizing the distribution of profits to investors despite the decline in profitability.
To stay informed about changes in financials or dividend disbursements, investors should pay close attention to the company's performance in the upcoming quarters.
[See current stock movements Nu Skin Enterprises on Benzinga.](https://www.benzinga.com/quote/Nu Skin Enterprises (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>))
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Dividends

Navigating Challenges and Investor Rewards: Nu Skin Enterprises Ensures Steady Distribution amidst Changing Profits

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#39;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#39;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/"> Benzinga Pro</a>.
Here&rsquo;s the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3>Herbalife Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>)</h3>
<ul>
<li>On Feb. 14, Herbalife reported mixed fourth-quarter financial results. The company&rsquo;s stock fell around 32% over the past five days and has a <a href="https://www.benzinga.com/quote/HLF">52-week low of $6.68 </a>.</li>
<li>RSI Value: 28.29</li>
<li>HLF Price Action: Shares of Herbalife gained 2.4% to close at $8.26 on Tuesday.</li>
</ul>
<h3>Universal Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/uvv#NYSE">UVV</a>)</h3>
<ul>
<li>On Feb. 7, Universal posted third-quarter earnings of $2.12 per share, up from $1.67 per share in the year-ago period. George C. Freeman, III, Chairman, President, and Chief Executive Officer of Universal, stated, &quot;Universal Corporation again delivered strong financial and operational performance in the third quarter of fiscal year 2024. Operating income and net income for the quarter were up 13% and 28%, respectively, relative to the third quarter of fiscal year 2023, which helped increase operating income and net income for the nine months of fiscal year 2024 by 20% and 13%, respectively, compared to the same period last fiscal year.&quot; The company&rsquo;s stock fell around 17% over the past month. It <a href="https://www.benzinga.com/quote/UVV"> has a 52-week low </a> of $44.40.</li>
<li>RSI Value: 22.77</li>
<li>UVV Price Action: Shares of Universal Corporation fell 0.8% to close at $49.35 on Tuesday.</li>
</ul>
<h3>Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>)</h3>
<ul>
<li>On Feb. 14, Nu Skin reported fourth-quarter financial results. &quot;While we continue to work toward our long-term vision of becoming the world&rsquo;s leading integrated beauty and wellness platform, our progress was impacted by persistent macro-economic pressures and disruptions associated with transforming our business,&quot; said Ryan Napierski, Nu Skin president and CEO. The company&rsquo;s stock fell around 28% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/NUS"> low of $12.89.</a></li>
<li>RSI Value: 21.93</li>
<li>NUS Price Action: Shares of Nu Skin fell 4.8% to close at $13.03 on Tuesday.</li>
</ul>
<h3>Stryve Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snax#NASDAQ">SNAX</a>)</h3>
<ul>
<li>On Feb. 1, Stryve Foods announced a significant expansion in its distribution network. The company&rsquo;s shares lost around 7% over the past five days. The company&rsquo;s 52-week low is $1.35.</li>
<li>RSI Value: 26.87</li>
<li>SNAX Price Action: Shares of Stryve Foods fell 6.3% to close at $1.35 on Tuesday.</li>
</ul>
&nbsp;
Read More: <a href="https://www.benzinga.com/news/24/02/37209778/starbucks-regeneron-pharmaceuticals-and-2-other-stocks-insiders-are-selling"> Starbucks, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling </a>

Long Ideas

Penny Stocks

Pre-Market Outlook

SNAX

Top 4 Risk Off Stocks That May Explode In February

Thursday marks the last chance for investors to receive the next dividend payout from Nu Skin Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>). 
<h3>What's Happening</h3>
The company announced on Wednesday that it would pay shareholders a quarterly dividend of 6 cents per share. On Friday, Nu Skin Enterprises will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, the stock will likely open 6 cents lower than it would have opened on any other day.
In order to be eligible to receive a company's dividend, shareholders must own the stock prior to the ex-dividend date—in this case, Friday. Shareholders who own NUS as of the end of Thursday's session are eligible to receive the 6 cents dividend payout for every share that they own. 
According to the company, this dividend will be paid out to shareholders on March 06, 2024. Investors will then be able to either reinvest those dividends back into the stock or use the payment in some other way. 
To stay up-to-date with the companies that are announcing their dividends, <a href="https://www.benzinga.com/calendars/dividends">click here</a> to visit our Dividends Calendar.

Nu Skin Enterprises's Ex-Dividend Date Is Friday, Here's What You Need To Know

Shares of Herbalife Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>) fell sharply in today&rsquo;s session following <a href="https://www.benzinga.com/quote/HLF/earnings">weak quarterly earnings</a>.
Herbalife posted adjusted earnings of 28 cents per share, missing market estimates of 39 cents per share. The company&rsquo;s quarterly sales came in at $1.22 billion versus expectations of $1.19 billion.
Herbalife shares dipped 35.7% to $7.55 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>JX Luxventure Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jxjt#NASDAQ">JXJT</a>) shares jumped 377% to $6.21 following H1 results.</li>
<li>Dunxin Financial Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxf#NYSE">DXF</a>) surged 204% to $1.11 after gaining around 5% on Wednesday.</li>
<li>China Natural Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chnr#NASDAQ">CHNR</a>) jumped 143% to $2.68 after gaining around 10% on Wednesday.</li>
<li>The Children&#39;s Place, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plce#NASDAQ">PLCE</a>) rose 101% to $29.23.</li>
<li>Nano-X Imaging Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nnox#NASDAQ">NNOX</a>) shares climbed 54.7% to $9.84. Nvidia reported a 59,632 share stake in Nano X Imaging.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) gained 54% to $0.1710.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) gained 53% to $3.4499. According to data from Benzinga Pro, BlackRock reported a 5.6% passive stake in SoundHound AI after the market close. Traders also appear to be circling a filing from Nvidia in which the company disclosed positions in several companies, including SoundHound AI.</li>
<li>Orgenesis Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/orgs#NASDAQ">ORGS</a>) climbed 30.2% to $0.4362. Orgenesis 10% owner Jacob Safier acquired a total of 365,140 shares at an average price of $0.58.</li>
<li>Pegasystems Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pega#NASDAQ">PEGA</a>) jumped 27.8% to $64.84 after the company reported better-than-expected fourth-quarter financial results and issued FY24 EPS and revenue guidance above estimates.</li>
<li>JFrog Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frog#NASDAQ">FROG</a>) shares gained 27% to $47.09 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS and revenue guidance above estimates.</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) rose 26% to $1.1800.</li>
<li>American Well Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amwl#NASDAQ">AMWL</a>) jumped 25% to $1.39 following quarterly results.</li>
<li>Datasea Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtss#NASDAQ">DTSS</a>) gained 25% to $11.24. DataSea announced a $30 million 5G multimodal communication technology service agreement.</li>
<li>AppLovin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>) rose 22% to $57.16 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Ultralife Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ulbi#NASDAQ">ULBI</a>) gained 21.4% to $9.60 following upbeat quarterly results.</li>
<li>Shake Shack Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shak#NYSE">SHAK</a>) rose 18.6% to $92.60 after the company reported better-than-expected quarterly financial results and issued guidance.</li>
<li>Digital World Acquisition Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dwac#NASDAQ">DWAC</a>) jumped 18.6% to $51.65 after the company announced the U.S. Securities and Exchange Commission declared its registration statement on Form S-4 effective.</li>
<li>Sylvamo Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slvm#NYSE">SLVM</a>) gained 18.5% to $53.94 following upbeat earnings.</li>
<li>DNOW Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dnow#NYSE">DNOW</a>) jumped 18.4% to $11.62 following strong quarterly results.</li>
<li>Express, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/expr#NYSE">EXPR</a>) climbed 18.1% to $2.4111.</li>
<li>Organon &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogn#NYSE">OGN</a>) shares rose 16.5% to $19.07 after the company reported better than expected Q4 2023 earnings and issued 2024 guidance.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) shares surged 15.9% to $1.25 after falling 6% on Wednesday.</li>
<li>Rail Vision Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rvsn#NASDAQ">RVSN</a>) gained 15.2% to $6.76.</li>
<li>Organon &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ogn#NYSE">OGN</a>) rose 14.9% to $18.80 after the company reported better than expected fourth quarter earnings and issued 2024 guidance.</li>
<li>Zebra Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zbra#NASDAQ">ZBRA</a>) rose 14% to $288.44 after the company reported fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>Appian Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/appn#NASDAQ">APPN</a>) climbed 13.8% to $37.97 after the company reported fourth-quarter financial results above estimates.</li>
<li>Zebra Technologies Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zbra#NASDAQ">ZBRA</a>) rose 12.7% to $285.24 after the company reported fourth-quarter financial results and issued first-quarter guidance above estimates.</li>
<li>Informatica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/infa#NYSE">INFA</a>) gained 12.6% to $33.91 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Patterson-UTI Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pten#NASDAQ">PTEN</a>) rose 12.3% to $11.61 following strong sales.</li>
<li>Reliance Steel &amp; Aluminum Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rs#NYSE">RS</a>) rose 10.4% to $325.15 after the company reported fourth-quarter earnings above estimates and issued above-consensus first-quarter FY24 adjusted EPS.</li>
<li>EPAM Systems, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/epam#NYSE">EPAM</a>) gained 10.3% to $288.44 after the company reported fourth-quarter financial results and issued first-quarter revenue guidance above estimates.</li>
<li>Cognex Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cgnx#NASDAQ">CGNX</a>) rose 9.8% to $39.70 following upbeat earnings.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) shares jumped 8.8% to $4.64 after the company announced raising $175 million in new capital financing from TotalEnergies and Global Infrastructure Partners and fourth-quarter financial results below estimates.</li>
<li>Lyft, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyft#NASDAQ">LYFT</a>) rose 8.6% to $17.82. Lyft recently reported fourth-quarter financial results and issued guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) fell 45.7% to $0.0862 following second-quarter results.</li>
<li>Beamr Imaging Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmr#NASDAQ">BMR</a>) fell 44% to $9.00.</li>
<li>Earlyworks Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elws#NASDAQ">ELWS</a>) shares fell 39.1% to $0.7979.</li>
<li>Upexi, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upxi#NASDAQ">UPXI</a>) shares declined 30.4% to $0.96 following weak quarterly results.</li>
<li>Telomir Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/telo#NASDAQ">TELO</a>) shares fell 30.1% to $8.31 after jumping around 70% on Wednesday.</li>
<li>Fastly, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsly#NYSE">FSLY</a>) shares tumbled 29.2% to $16.67 after the company reported mixed fourth-quarter financial results.</li>
<li>Cineverse Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnvs#NASDAQ">CNVS</a>) shares fell 27.2% to $1.7120 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Aurinia Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auph#NASDAQ">AUPH</a>) fell 26.1% to $5.89 after the company reported mixed fourth-quarter financial results and said it did not find a buyer after conducting a strategic business review.</li>
<li>Clean Energy Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cety#NASDAQ">CETY</a>) dipped 26% to $0.7989.</li>
<li>Renalytix Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnlx#NASDAQ">RNLX</a>) fell 25.4% to $0.9001 after the company posted weak quarterly sales.</li>
<li>Innodata Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/inod#NASDAQ">INOD</a>) fell 25.2% to $9.16 after Wolfpack Research issued a report on the company and said it is short the stock.</li>
<li>Sabre Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sabr#NASDAQ">SABR</a>) dipped 23.3% to $3.3850 after the company reported mixed quarterly financial results.</li>
<li>Udemy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/udmy#NASDAQ">UDMY</a>) fell 20.8% to $11.08 after the company reported fourth-quarter financial results.</li>
<li>Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>) shares fell 18.8% to $14.15 after the company reported fourth-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wst#NYSE">WST</a>) fell 18.5% to $332.37 after the company reported mixed fourth-quarter financial results and issued 2024 adjusted EPS and sales guidance below estimates.</li>
<li>Twilio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twlo#NYSE">TWLO</a>) dipped 13.8% to $62.29 after the company reported fourth-quarter financial results.</li>
<li>The Manitowoc Company, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtw#NYSE">MTW</a>) fell 12.6% to $14.36 following weak earnings.</li>
<li>Manchester United plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/manu#NYSE">MANU</a>) fell 12.1% to $18.90.</li>
<li>Hanesbrands Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hbi#NYSE">HBI</a>) fell 11.6% to $4.17 following weak results.</li>
<li>PENN Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/penn#NASDAQ">PENN</a>) fell 10.2% to $20.17 following weak results.</li>
<li>Insight Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nsit#NASDAQ">NSIT</a>) dipped 5.5% to $182.10 after the company reported fourth-quarter financial results and issued FY24 EPS guidance below estimates.</li>
<li>Deere &amp; Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/de#NYSE">DE</a>) fell 4.7% to $366.79 after the company reported first-quarter earnings and lowered FY24 net income guidance.</li>
<li>Rollins, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rol#NYSE">ROL</a>) fell 4.1% to $42.42 following quarterly results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/02/37150356/disney-progressive-leidos-and-more-cnbcs-final-trades"> Disney, Progressive, Leidos And More: CNBC&#39;s &#39;Final Trades&#39;</a>

Intraday Update

Movers

AMWL

APPN

AUPH

CETY

CGNX

CHNR

CNVS

DNOW

DTSS

DWAC

ELWS

EPAM

EXPR

FROG

FSLY

IFBD

INFA

INOD

JXJT

LYFT

MANU

NNOX

NSIT

ORGS

PEGA

PENN

PLCE

PTEN

RNLX

ROMA

RVSN

SABR

SHAK

SLVM

SOUN

SPWR

TELO

TWLO

UDMY

ULBI

UPXI

ZBRA

Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Nu Skin shares are trading lower after the company reported Q4 financial results.

Shares of AppLovin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/app#NASDAQ">APP</a>) rose sharply in today&rsquo;s pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/02/37145288/applovin-q4-earnings-revenue-beat-estimates-expands-buy-back-program-by-1-25b">fourth-quarter financial results</a>.
AppLovin reported quarterly earnings of 49 cents per share which beat the analyst consensus estimate of 36 cents. The company reported quarterly sales of $953.26 million, beating the analyst consensus estimate of $928.17 million.
AppLovin shares jumped 22.3% to $57.30 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>China Natural Resources, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/chnr#NASDAQ">CHNR</a>) gained 409% to $5.60 in pre-market trading after gaining around 10% on Wednesday.</li>
<li>Meihua International Medical Technologies Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mhua#NASDAQ">MHUA</a>) shares jumped 70.2% to $1.89 in pre-market trading after surging around 19% on Wednesday.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) gained 69.8% to $3.83 in pre-market trading. According to data from Benzinga Pro, BlackRock reported a 5.6% passive stake in SoundHound AI after the market close. Traders also appear to be circling a filing from Nvidia in which the company disclosed positions in several companies, including SoundHound AI.</li>
<li>Nano-X Imaging Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nnox#NASDAQ">NNOX</a>) shares rose 46.2% to $9.30 in pre-market trading. Nvidia reported a 59,632 share stake in Nano X Imaging.</li>
<li>Roma Green Finance Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roma#NASDAQ">ROMA</a>) shares surged 38% to $1.49 in pre-market trading after falling 6% on Wednesday.</li>
<li>Dunxin Financial Holdings Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxf#NYSE">DXF</a>) shares gained 34.2% to $0.49 in pre-market trading after gaining around 5% on Wednesday.</li>
<li>Greenpro Capital Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grnq#NASDAQ">GRNQ</a>) shares rose 24.3% to $1.74 in pre-market trading after gaining around 23% on Wednesday.</li>
<li>JFrog Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/frog#NASDAQ">FROG</a>) shares gained 22.1% to $44.92 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS and revenue guidance above estimates.</li>
<li>Informatica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/infa#NYSE">INFA</a>) gained 17.3% to $35.34 in pre-market trading after the company reported better-than-expected fourth-quarter financial results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Treasure Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tgl#NASDAQ">TGL</a>) shares dipped 40.4% to $0.0945 in pre-market trading following second-quarter results.</li>
<li>Cineverse Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cnvs#NASDAQ">CNVS</a>) shares fell 31.9% to $1.60 in pre-market trading after the company reported worse-than-expected third-quarter financial results.</li>
<li>Upexi, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/upxi#NASDAQ">UPXI</a>) shares declined 29.5% to $0.9724 in pre-market trading following weak quarterly results.</li>
<li>Nu Skin Enterprises, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nus#NYSE">NUS</a>) shares fell 24% to $13.25 in pre-market trading after the company reported fourth-quarter financial results.</li>
<li>Fastly, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsly#NYSE">FSLY</a>) shares tumbled 23.1% to $18.10 in pre-market trading after the company reported mixed fourth-quarter financial results.</li>
<li>enGene Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/engn#NASDAQ">ENGN</a>) shares fell 13.3% to $14.30 in pre-market trading. enGene shares jumped around 116% on Wednesday after the company announced an oversubscribed $200 million private placement financing.</li>
<li>Herbalife Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>) shares declined 12.3% to $10.30 in pre-market trading following weak quarterly earnings.</li>
<li>Twilio Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/twlo#NYSE">TWLO</a>) dipped 12.1% to $63.51 in pre-market trading after the company reported fourth-quarter financial results.</li>
<li>Telomir Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/telo#NASDAQ">TELO</a>) shares fell 10.7% to $10.64 in pre-market trading after jumping around 70% on Wednesday.</li>
<li>Cisco Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/csco#NASDAQ">CSCO</a>) fell 5.2% to $47.67 in pre-market trading following second-quarter results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37149816/cisco-deere-and-3-stocks-to-watch-heading-into-thursday"> Cisco, Deere And 3 Stocks To Watch Heading Into Thursday </a>

CSCO

ENGN

GRNQ

MHUA

Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Repairing Olaplex: 3 Catalysts That Evidence A Turnaround

CNH Industrial, Parsons and more join S&P MidCap 400

An announcement from Nu Skin ( ($NUS) ) is now available. Nu Skin Enterprises, Inc. has expanded its Board of Directors by appointing Mark A. Zorko...

Nu Skin Expands Board with Mark Zorko's Appointment

Multi-Level Marketing: Stagnation Or Something Worse?

Nu Skin: Betting On A Potential Comeback

Citi lowered the firm's price target on Nu Skin (NUS) to $6.75 from $11.50 and keeps a Neutral rating on the shares. The analyst updated estimates ...

Nu Skin price target lowered to $6.75 from $11.50 at Citi

Nu Skin Q3 2024 Earnings Preview

Nu Skin declares $0.06 dividend

Nu Skin Enterprises, Inc. (NUS) Q3 2024 Earnings Call Transcript

Nu Skin Enterprises, Inc. 2024 Q3 - Results - Earnings Call Presentation

ADMA

ADNT

AMCX

CHCT

COTY

CSWI

CVGW

EHAB

HELE

HLNE

INSP

IVOG

IVOO

LFVN

MERC

MTEX

NATR

OLPX

PGNY

PSCE

PSCH

PSCT

REGL

RILY

TGTX

TUPBQ

USNA

VIOO

VNOM

VREX

WOLF

XMHQ

XMLV

XMMO

ZEUS

Press Releases

Mavely Achieves Major Milestones: $675M+ Run Rate with Increased Growth and Creator Payouts

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

Social Media

New Data: Gen Z Most Likely to Trust Influencer Gift Recommendations, but Need the Most Touchpoints for a Sell

Nu Skin Enterprises to Announce Third Quarter 2024 Financial Results

Mavely Streamlines Creator Experience from Post to Purchase with New LinkDM and Button Partnerships and MyShop Upgrades

Nu Skin Introduces MYND360™, a New Line of Clinically Proven Supplements and Topicals for Mental Well-Being

Later Drives Full-Funnel Influencer Marketing Impact with New Affiliate Campaign Capabilities, Leveraging a Strategic Partnership with Mavely

Comments

Nu Skin Enterprises

Vendite allo scoperto

Nu Skin Enterprises (NYSE:NUS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO